ArticleFrontiers in endocrinology2026
A nomogram integrating machine learning with clinical predictors for osteosarcopenia risk prediction in type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Type 2 diabetes mellitus (T2DM) predisposes patients to osteosarcopenia, a debilitating condition characterized by concurrent bone loss and muscle wasting. This study aimed to develop and internally validate a nomogram for predicting osteosarcopenia risk in T2DM patients aged ≥ 40 years. Methods: The test cohort included 5,412 hospitalized T2DM patients (January 2010-July 2024), and the temporal validation cohort included 1,671 patients (August 2024-December 2025) from the First Affiliated Hospital of Fujian Medical University. Logistic regression and machine learning algorithms (Boruta, random forest, LASSO) were combined for feature selection. The nomogram was constructed via multivariable logistic regression. We carried out receiver operating characteristic (ROC) curve analysis, calibration, decision curve analysis (DCA), and bootstrap validation for assessing the nomogram. Restricted cubic splines were employed for exploring potential nonlinear associations. Results: Eight independent predictors, which encompassed gender, age, BMI, WHtR, fracture history, diabetic foot ulcer (DFU), smoking status, and diabetic kidney disease (DKD), were identified. These predictors were incorporated into the nomogram. The nomogram achieved AUCs of 0.864 and 0.904 in the test cohort and validation cohort, respectively. Accordingly, favorable calibration and positive net benefit on DCA was demonstrated. Higher BMI served as a protective factor (OR = 0.56, 95% CI: 0.53-0.59). Besides, higher WHtR acted as a risk factor (OR = 1.47, 95% CI: 1.28-1.69). Restricted cubic spline analysis revealed a significant negative nonlinear relationship between BMI and osteosarcopenia risk, and a significant positive nonlinear relationship between WHtR and osteosarcopenia risk. Conclusion: This nomogram, based on eight readily available clinical variables, exhibits excellent discriminative performance and clinical utility for predicting osteosarcopenia risk in T2DM patients aged ≥ 40 years. Further multicenter external validation is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.